Synthetic Biology Companies join BIA, Trade Association Forms New Group for Emerging Sector
News Apr 04, 2013
Synbio is the design and engineering of biologically based parts, novel devices and systems as well as the redesign of existing, natural biological systems. It has the potential to deliver important new applications and improve existing industrial processes - resulting in economic growth and job creation.
The eight companies founding the BIA synbio group are: Algenuity, Biosyntha, Genabler, Green Biologics, Oxitec, Prokarium, Synpromics and Synthace.
Lionel Clarke, Chairman of the UK Synbio Leadership Council said:
"I am extremely pleased to see that the Roadmap is already delivering such a positive impact - raising the profile of Synthetic Biology companies within the UK, and galvanising action aligned with our vision. This will provide a valuable forum for bringing together and representing the ongoing interests of this rapidly developing industrial community."
Steve Bates, BIA Chief Executive Officer, said:
"I am delighted to welcome these exciting companies into membership of the BIA. I believe these companies will benefit significantly from joining a trade association that has a proud and strong track record in representing innovative start-up life science companies.
"Additionally, our expertise in finance, intellectual property, regulation and policy will help accelerate the development of these companies and enable them to exploit their potential faster. This will help the UK to deliver on its plan to be a world leader in this space in the coming years.
"The BIA shares the vision of the UK roadmap for synbio and through the working group will help enable companies to develop these technologies for commercial use.
"Existing BIA members, who are largely in the healthcare arena, are likely to be a key user of synbio tools for drug development in future, so by bringing the synbio companies under the BIA umbrella there are strong synergies and a shared community that all companies will find useful."
Tim Fell, Non-executive Director at Synthace, said:
"This group is very well placed to ensure that all see the wide ranging opportunities this emergent technology presents. Through stakeholder discussion - a key element of the synbio roadmap - we hope this group will help remove barriers, reduce commercial and technical risk, build a community of practitioners and create momentum through critical mass, thereby accelerating our collective journey to market."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.